3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Kidney Transplantation
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Adenocarcinoma, Clear Cell
1
Interventions
Cyclophosphamide
8
Rituximab
5
fludarabine
4
Vincristine
4
Prednisone
4
Doxorubicin
4
fludarabine phosphate
3
Tacrolimus
3
Mycophenolic Acid
3
Etoposide
3
Busulfan
3
venetoclax
2
entrectinib
2
atezolizumab
2
alectinib
2
acalabrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bortezomib
2
trametinib
1
pertuzumab
1
pembrolizumab
1
obinutuzumab
1
liposomal doxorubicin
1
isatuximab
1
ibrutinib
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Alemtuzumab
×
1 year
×
Clear all
No trials found.